What is the recommended dosing and administration technique for intraperitoneal vancomycin in patients with peritoneal dialysis-associated peritonitis?

Intraperitoneal Vancomycin Administration for Peritoneal Dialysis-Associated Peritonitis

For peritoneal dialysis-associated peritonitis, administer intraperitoneal vancomycin as a loading dose of 30 mg/kg (based on actual body weight) in a single exchange, followed by maintenance dosing of either 30 mg/kg every 5-7 days (intermittent) or 30 mg/L in each dialysate exchange (continuous), with serum level monitoring on day 5 to ensure therapeutic concentrations of 15-20 mg/L. 1, 2

Dosing Regimens

Loading Dose

• Initial dose: 30 mg/kg based on actual body weight, administered intraperitoneally in a single exchange 1, 2
• This loading dose achieves therapeutic serum concentrations (>15 mg/L) in most patients 1
• The FDA label confirms that approximately 60% of an intraperitoneal vancomycin dose is absorbed systemically within 6 hours, achieving serum concentrations around 10 mcg/mL with 30 mg/kg dosing 3

Maintenance Dosing Options

Intermittent Dosing:

• 30 mg/kg every 5-7 days depending on peritoneal dialysis modality 1, 2
• For continuous ambulatory peritoneal dialysis (CAPD): repeat every 5-7 days 4
• This regimen achieves therapeutic serum levels after the loading dose but may result in subtherapeutic levels initially in 60% of patients 1

Continuous Dosing:

• 30 mg/L added to each dialysate exchange after the loading dose 2
• Recent pharmacokinetic modeling suggests 50 mg/L in each dwell may be more appropriate to prevent underdosing 5
• Continuous dosing may be preferable as it more consistently maintains therapeutic intraperitoneal concentrations above the minimum inhibitory concentration (MIC) 6

Administration Technique

Preparation and Route

• Vancomycin must be given by secure intravenous or intraperitoneal route only—never intramuscular due to tissue irritation, pain, and necrosis risk 3
• For intraperitoneal administration, add the calculated vancomycin dose to the dialysate bag 2
• The FDA label notes that while intraperitoneal vancomycin is absorbed systemically, the safety and efficacy of intraperitoneal administration have not been established in adequate and well-controlled trials 3

Important Caveat

• Chemical peritonitis has been reported with intraperitoneal vancomycin during CAPD, presenting as cloudy dialysate with or without abdominal pain and fever, which resolves after discontinuation 3

Monitoring Strategy

Serum Level Monitoring

• Draw serum vancomycin level on day 5 (before the second dose if using intermittent dosing) 1, 7
• Target trough serum concentration: 15-20 mg/L for serious infections 8
• A day 5 trough level <10.1 mg/L is associated with increased risk of short-term adverse outcomes including treatment failure, relapse, and need for hemodialysis transfer 7
• Serum levels >15 mg/L were achieved in 98% of patients with intermittent dosing, but this doesn't guarantee therapeutic intraperitoneal levels 6

Intraperitoneal Concentration Considerations

• Despite adequate serum levels, 23% of patients may have subtherapeutic peritoneal dialysate effluent concentrations (<4 mg/L) at the end of a 4-hour dwell 6
• The correlation between serum and peritoneal dialysate concentrations is poor (R² = 0.18), meaning serum levels don't reliably predict intraperitoneal concentrations 6
• This supports the potential advantage of continuous over intermittent dosing 6

Factors Affecting Vancomycin Levels

Patient-Specific Considerations

• Higher peritoneal transport status (high/high-average transporters) is associated with suboptimal serum vancomycin levels due to increased peritoneal clearance 7
• Residual kidney function does not significantly correlate with serum vancomycin levels in most studies 1
• Dosing should be based on actual body weight, including in obese patients 8

Dose Adjustments

• If day 5 serum level is subtherapeutic (<15 mg/L), consider switching to continuous dosing or increasing the intermittent dose 1
• Recent pharmacokinetic modeling suggests that current intermittent dosing may lead to underdosing in a large proportion of patients 5
• For patients with unstable renal function or receiving concurrent nephrotoxic agents, more frequent monitoring is warranted 8

Clinical Outcomes

Efficacy

• Both intermittent and continuous vancomycin regimens achieve clinical resolution in 78-100% of peritonitis episodes 1, 2
• Mean time to macroscopic clearing of dialysate: 3.2 days 2
• Recurrence rates within 1 month are low (approximately 10-14%) and similar between dosing strategies 2

Safety Monitoring

• Monitor for nephrotoxicity: defined as ≥2-3 consecutive serum creatinine increases of 0.5 mg/dL or 150% from baseline 8
• Trough monitoring is most important for patients with aggressive dosing targeting 15-20 mg/L or those receiving concurrent nephrotoxins 8
• The FDA label notes that vancomycin can cause reversible neutropenia, warranting periodic leukocyte monitoring in patients on prolonged therapy 3

Common Pitfalls to Avoid

• Don't assume therapeutic serum levels guarantee therapeutic intraperitoneal levels—the correlation is poor 6
• Don't draw vancomycin levels at inappropriate times—this occurred frequently in clinical practice, with levels drawn when outpatient visits didn't align with dosing schedules 1
• Don't use peak level monitoring—trough levels are the most accurate and practical monitoring method 8
• Avoid intermittent dosing if consistent intraperitoneal exposure is critical, as it may not maintain concentrations markedly above MIC between doses 6
• Don't ignore high peritoneal transport status—these patients are at higher risk for suboptimal vancomycin levels and may need dose adjustments or more frequent monitoring 7